论文部分内容阅读
采用PCR—SSCP及RNA打点杂交技术对18对骨恶性肿瘤及相应瘤旁组织同时进行P_(21)基因突变及表达程度的检测,并结合3年的随访结果对P_(21)基因突变及高表达与骨肿瘤患者的预后进行了探讨。结果发现:①18例骨肿瘤中有3例突变,4例呈高表达,其中3例为伴有突变标本,还有1例为恶性纤维组织细胞瘤标本。②P_(21)突变或高表达患者与P_(21)突变或高表达患者之间的死亡率存在显著性差异(P<0.05)。结论:P_(21)基因以突变、高表达方式参与骨肿瘤发生发展,检测P_(21)基因有无突变或高表达可辅助判断骨恶性肿瘤病程及预后。
Using PCR-SSCP and RNA dot hybridization techniques, 18 pairs of bone malignancies and corresponding paraneoplastic tissue were simultaneously tested for the mutation and expression of P21 mutations, combined with 3 years of follow-up results for P 21 mutations and high The prognosis of patients with bone tumors is discussed. The results showed that: of the 118 cases of bone tumors, 3 were found to have mutations and 4 were highly expressed. Among them, 3 cases were accompanied by mutations, and 1 case was malignant fibrous histiocytoma. There was a significant difference in mortality between 2P_(21) mutant or high expression patients and P_(21) mutant or high expression patients (P<0.05). Conclusion: The P_(21) gene is involved in the development of bone tumors with mutation and high expression. Detection of P_(21) gene mutation or high expression can help determine the course and prognosis of bone cancer.